Pages that link to "Q67509807"
Jump to navigation
Jump to search
The following pages link to Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India (Q67509807):
Displaying 30 items.
- Visceral leishmaniasis: new health tools are needed (Q24815791) (← links)
- Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis (Q27011766) (← links)
- Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective (Q28073426) (← links)
- Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004 (Q28283745) (← links)
- Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom (Q28342808) (← links)
- Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent (Q28475431) (← links)
- Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India (Q33779256) (← links)
- Liposomal amphotericin B and leishmaniasis: dose and response (Q33929854) (← links)
- Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis (Q33980941) (← links)
- Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches (Q34141558) (← links)
- Antimony Toxicity (Q34164336) (← links)
- Miltefosine (Impavido): the first oral treatment against leishmaniasis (Q34265578) (← links)
- Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells (Q34483607) (← links)
- Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda (Q34768663) (← links)
- Paromomycin (Q34864208) (← links)
- Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects (Q35135879) (← links)
- Visceral leishmaniasis in Malta--an 18 year paediatric, population based study (Q35266494) (← links)
- Leishmania and human immunodeficiency virus coinfection: the first 10 years (Q35374078) (← links)
- Human antiprotozoal therapy: past, present, and future. (Q35535171) (← links)
- Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs (Q35606296) (← links)
- Therapeutic options for visceral leishmaniasis (Q37333942) (← links)
- Drug combinations for visceral leishmaniasis (Q37792751) (← links)
- Chemotherapy of leishmaniasis: present challenges (Q39011875) (← links)
- Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient (Q42072580) (← links)
- Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health (Q43167558) (← links)
- Visceral leishmaniasis: new drugs (Q44800584) (← links)
- Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. (Q53950094) (← links)
- A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. (Q53950097) (← links)
- [Treatment of infantile visceral leishmaniasis] (Q54105467) (← links)
- Ribosomes of Leishmania are a target for the aminoglycosides (Q71592112) (← links)